haematology
Blood cancers

Blood cancer patients show poor response to first dose of COVID-19 vaccine

People with haematological cancers show poor immune responses after a single dose of Pfizer’s COVID-19 vaccine, highlighting the need for patients to receive the second dose as soon as possible, researchers say. A prospective study involving 151 cancer patients in the UK found that three weeks following the first dose of mRNA-based SARS-CoV-2 BNT162b2 vaccine ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic